Judge Rejects KV Sanctions Bid In Ritalin ANDA Suit

Law360, New York (July 22, 2008, 12:00 AM EDT) -- KV Pharmaceutical Co. has lost its bid for sanctions against pharmaceutical firms Celgene Corp. and Novartis Pharma AG for failing to conduct an infringement analysis before suing KV to stop it from marketing a generic version of Ritalin LA, which treats attention deficit disorder.

Judge Susan D. Wigenton of the U.S. District Court for the District of New Jersey denied KV’s motion with prejudice on July 17, holding that a patent owner can file suit after determining a party has submitted an Abbreviated New Drug Application...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.